Thalidomide-O-amido-C8-NH2

Cat. No.:	HY-107439	
CAS No.:	1950635-15-0	
Molecular Formula:	$C_{23}H_{30}N_4O_6$	O NH2
Molecular Weight:	458.51	
Target:	E3 Ligase Ligand-Linker Conjugates	
Pathway:	PROTAC	0 0
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.	

BIOLOGICAL ACTIVITY		
DIOEOGICAL ACTIVITY		
Description	Thalidomide-O-amido-C8-NH2 (Cereblon Ligand-Linker Conjugates 2), a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide based cereblon ligand and a linker, can be used in the synthesis of PROTACs ^[1] .	
IC ₅₀ & Target	Cereblon	
In Vitro	Thalidomide-O-amido-C8-NH2 is a degron-linker (refer to Compound DL7-TL). The PROTAC linker is bound lo at least one targeting ligand. Degron-linker-targeting ligand, wherein the linker is covalently bound lo at least one degron and at least one targeting ligand, the degron is a compound capable of binding to an ubiquitin ligase such as an E3 ubiquitin ligase (e g, cereblon), and the targeting ligand is capable of binding to the targeted protein (s) ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.	

CUSTOMER VALIDATION

• Bioconjug Chem. 2020 Nov 18;31(11):2564-2575.

See more customer validations on www.MedChemExpress.com

REFERENCES

Page 1 of 1

[1]. James Bradner, et al. Methods to induce targeted protein degradation through bifunctional molecules. WO 2017024317 A2.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898 F

Fax: 609-228-5909

909 E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA



Tel: 609-228-6898